Skip to main
ELTX

ELTX Stock Forecast & Price Target

ELTX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Elicio Therapeutics is a promising biopharmaceutical company with a strong focus on developing effective immunotherapies to treat various types of cancer. Their innovative Amphiphile (AMP) technology and successful clinical trials for ELI-002 have positioned them as a leader in the market. With a dedicated CEO and potential for high sales, ELTX has a positive outlook for future growth.

Bears say

Elicio Therapeutics is a biotechnology company that focuses on developing novel immunotherapies for the treatment of cancer. While its proprietary AMP technology has shown potential in preclinical studies, the company's clinical pipeline includes only one candidate, ELI-002 7P, which is currently being evaluated in a Phase 2 study for a limited population of mKRAS pancreatic cancer patients. Furthermore, the company may face financial challenges in the future as it may need to raise additional capital before reaching profitability, which could result in equity dilution. Additionally, regulatory and clinical risks could potentially delay or limit the success of ELI-002 7P.

ELTX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Elicio Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Elicio Therapeutics Inc (ELTX) Forecast

Analysts have given ELTX a Strong Buy based on their latest research and market trends.

According to 4 analysts, ELTX has a Strong Buy consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Elicio Therapeutics Inc (ELTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.